Human-derived lactobacillus frementum mg4231 or lactobacillus frementum mg4244 strain having anti-obesity activity and composition comprising same

Abstract

The present invention relates to human-derived Lactobacillus fermentum MG4231 or Lactobacillus fermentum MG4244 and to a pharmaceutical composition for the prevention or treatment of obesity-related diseases, containing the same as an active ingredient, and a food composition, quasi-drug composition and functional health food. The Lactobacillus fermentum MG4231 strain or MG4244 strain of the present invention exhibits anti-obesity activity that inhibits lipase enzyme activity, preadipocyte differentiation and neutral lipid accumulation, has high autoaggregation ability to thus show excellent colony formation ability on the epithelial cells of the digestive tract, and is resistant to acid and bile. Thereby, the Lactobacillus fermentum MG4231 strain or the MG4244 strain can be variously utilized in a pharmaceutical composition for the prevention and treatment of obesity-related diseases, and a food composition, quasi-drug composition and functional health food.

1 - 6 . (canceled) 
     
     
         7 . A method for treating an obesity related disease, comprising:
 administering to a subject in need thereof a composition comprising an effect amount of a vaginal-lining-derived  Lactobacillus fermentum  MG4231 strain (Accession number: KCTC 13593BP) and at least one excipient   
     
     
         8 . The method of  claim 7 , wherein the obesity-related disease is at least one selected from the group consisting of fatty liver, type 2 diabetes, hyperlipidemia, a cardiovascular disease, arteriosclerosis and a lipid-related metabolic syndrome. 
     
     
         9 . The method of  claim 7 , wherein the composition is a pharmaceutical composition. 
     
     
         10 . The method of  claim 7 , wherein the composition is a food composition. 
     
     
         11 . The method of  claim 7 , wherein the composition is a functional health food composition. 
     
     
         12 . The method of  claim 7 , wherein the composition is a quasi-drug composition. 
     
     
         13 . The method of  claim 7 , wherein the vaginal-lining-derived  Lactobacillus fermentum  MG4231 strain inhibits neutral lipid accumulation, acid resistance, bile resistance or autoaggregation ability. 
     
     
         14 . A composition comprising a vaginal-lining-derived  Lactobacillus fermentum  MG4231 strain (Accession number: KCTC 13593BP) and at least one excipient.